New Zealand Data Sheet

1. **NILSTAT** (500,00 I.U. tablets, 20,000 I.U./g vaginal cream, 100,000 I.U./mL oral drops, 500,000 I.U. capsules)

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**
   - Nystatin - 500,000 I.U. tablet
   - Nystatin - 500,000 I.U. capsules
   - Nystatin - 20,000 I.U./g vaginal cream
   - Nystatin - 100,000 I.U./mL oral drops

3. **PHARMACEUTICAL FORM**
   - **NILSTAT tablets:**
     Round, buff (deep yellow) tablets each containing 500,000 units of nystatin.
   - **NILSTAT capsules:**
     Buff coloured, hard shell capsules with the inscription 'Nilstat'. Each capsule contains 500,000 units of nystatin.
   - **NILSTAT vaginal cream:**
     Each gram of cream contains 20,000 units of nystatin in a water miscible base.
   - **NILSTAT oral drops:**
     Each mL contains 100,000 units of nystatin in a sucrose suspension.

4. **CLINICAL PARTICULARS**
4.1 **Therapeutic indications**
   - Nystatin is indicated for the treatment of cutaneous, mucocutaneous, oral, intestinal and vulvovaginal infections caused by Candida albicans.

   - **Tablets and capsules:** Intestinal candidiasis.
   - **Vaginal cream:** Local treatment of vulvovaginal candidiasis.
   - **Drops:** Infections of the oral cavity caused by Candida albicans.

4.2 **Dose and method of administration**
   - **Capsules and tablets:** Usual dosage - 500,000 to 1 million units (1 to 2 tablets or capsules) three times daily. Treatment should generally be continued for at least 48 hours after clinical cure to prevent a relapse.

   - **Vaginal cream:** The usual dosage is one full applicator of cream (5 g) inserted high in the vagina, once or twice daily. In most cases two weeks of therapy will be sufficient but more prolonged treatment may be necessary. It is important that therapy be continued during menstruation. Adjunctive measures such as therapeutic douches are unnecessary and sometimes inadvisable. Cleansing douches may be used by nonpregnant women, if desired, for aesthetic purposes.
**Drops:** Infants, children and adults - 1 mL (100,000 units) four times daily. The dose should be administered under the tongue or in the buccal cavity and held in the mouth and swirled around as long as possible before swallowing.

### 4.3 Contraindications

Hypersensitivity to nystatin or any of the other ingredients in the formulation (see section 6.1, List of excipients).

### 4.4 Special warnings and precautions for use

#### Drops

Nilstat oral drops should not be used for the treatment of systemic mycoses. If irritation or sensitization develops, treatment should be discontinued.

If there is a lack of therapeutic response, appropriate microbiological studies (e.g. KOH smear and/or cultures) should be repeated to confirm diagnosis of candidiasis and rule out other pathogens before instituting another course of therapy.

#### Vaginal Cream

While NILSTAT vaginal cream has only minimal effect on the tensile properties of latex rubber condoms, patients should be aware of the risk that condoms and diaphragms may be weakened when used with NILSTAT vaginal cream. Therefore, the use of contraceptive diaphragms and condoms with NILSTAT vaginal cream is not recommended.

**Use in immunocompromised patients**

Higher doses, for example 500,000 units 4 times daily may be needed. However, the use of alternate antifungal antibiotics is preferred for the treatment of oral thrush in patients with immunosuppression.

### 4.5 Interaction with other medicines and other forms of interaction

No data available.

### 4.6 Fertility, pregnancy and lactation

#### Fertility

No data available.

**Pregnancy**

**Category A**

Systemic absorption of nystatin is negligible after topical, vaginal, or oral administration. However, as with all medicines, caution should be exercised when nystatin is administered to pregnant women.
Lactation
No data available.

4.7 Effects on ability to drive and use machines
No data available.

4.8 Undesirable effects
Nystatin is well tolerated by all age groups even with prolonged administration. Large oral doses have occasionally produced diarrhoea, gastrointestinal distress, nausea and vomiting. There have been reports of allergic reactions to orally administered Nystatin, although these are rare.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/

4.9 Overdose
Symptomatology as described in the ADVERSE EFFECTS section would be expected. There are no specific guidelines relating to the treatment of overdosage with NILSTAT.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Nystatin is an antifungal antibiotic, produced by a strain of Streptomyces noursei, active against yeasts and yeast like fungi, including Candida albicans. The antifungal activity is probably due to the binding of sterols in the cell membrane of the fungus with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin has no appreciable activity against bacteria.

5.2 Pharmacokinetic properties
Nystatin is absorbed very sparingly following oral administration when given in the recommended doses. The minimal absorption from oral dosage forms may however, be sufficient to provoke an allergic reaction in hypersensitive patients. No detectable blood levels are obtained following topical or vaginal applications.

5.3 Preclinical safety data
No data available.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
In addition to Nystatin, the following excipients are present in NILSTAT products:

**Tablets:** Lactose monohydrate, ethylcellulose, magnesium stearate, sodium starch glycolate, carnauba wax, purified water, Opadry Yellow OY-2144A (hypromellose, macrogol 400, iron oxide yellow CI 77492, titanium dioxide).

**Capsules:** Lactose, magnesium stearate, ethanol, iron oxide yellow CI 77492, titanium dioxide, gelatin, isopropyl alcohol, shellac and carbon black CI 77266.

**Vaginal cream:** Emulsifying wax, isopropyl myristate, glycerol, sorbic acid and purified water (lactic acid or sodium hydroxide to adjust pH 4.5-5.5).

**Oral Drops:** Cherry flavor F1242, hydrochloric acid, methyl hydroxybenzoate, propyl hydroxybenzoate, sucrose, polysorbate 80, sodium calcium edetate (hydrate), purified water, bentonite, quinoline yellow, saponite, sodium hydroxide.

6.2 Incompatibilities
No data available.

6.3 Shelf life
24 months from data of manufacture.

6.4 Special precautions for storage
**Capsules, drops, tablets and vaginal cream:** Store at or below 25°C.

6.5 Nature and contents of container
**Capsules:** 500,000 I.U./capsule, 50's
**Drops:** 100,000 I.U./mL, 24 mL
**Tablets:** 500,000 I.U./tablet, 50's
**Vaginal cream:** 20,000 I.U./g, 75 g

6.6 Special precautions for disposal (and other handling)
No data available.

7. MEDICINE SCHEDULE

**Prescription Medicine**
NILSTAT Capsules
NILSTAT Tablets

**Restricted Medicine**
NILSTAT Oral Drops
NILSTAT Vaginal Cream

8. SPONSOR
Pharmacy Retailing (NZ) Limited
Trading as Healthcare Logistics
58 Richard Pearse Drive
Airport Oaks
Auckland
New Zealand

9. DATA OF FIRST APPROVAL
03 April 2013

10. DATE OF REVISION OF THE TEXT
May 2019

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All sections revised</td>
<td>Update to the SPC-style format</td>
</tr>
</tbody>
</table>